Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/sage/current-treatment-of-lupus-nephritis-KkpH1jnw5V
References (27)
-
G. Contreras, V. Pardo, B. Leclercq, O. Lenz, E. Tozman, Patricia O'Nan, D. Roth (2004)
Sequential therapies for proliferative lupus nephritis.The New England journal of medicine, 350 10
-
G. Moroni, B. Gallelli, S. Quaglini, G. Banfi, E. Rivolta, P. Messa, C. Ponticelli (2006)
Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 21 6
-
R. Cervera, M. Khamashta, J. Font, G. Sebastiani, A. Gil, P. Lavilla, J. Mejía, A. Aydintug, H. Chwalińska-Sadowska, E. Ramón, A. Fernández-Nebro, M. Galeazzi, Merete Valen, A. Mathieu, F. Houssiau, N. Caro, P. Alba, M. Ramos-Casals, M. Ingelmo, G. Hughes (2003)
Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period: A Comparison of Early and Late Manifestations in a Cohort of 1,000 PatientsMedicine, 82
-
D. Boumpas, H. Austin, J. Balow, E. Vaughan, Cheryl Yarboro, J. Klippel, A. Steinberg (1992)
Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritisThe Lancet, 340
-
M. Urowitz, D. Ibañez, Y. Ali, D. Gladman (2007)
Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide.The Journal of rheumatology, 34 7
-
R. Furie (2006)
Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus.Rheumatic diseases clinics of North America, 32 1
-
P. Sfikakis, J. Boletis, G. Tsokos (2005)
Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the futureCurrent Opinion in Rheumatology, 17
-
F. Houssiau, C. Vasconcelos, D. D'cruz, G. Sebastiani, Enrique Ed, M. Danieli, D. Abramovicz, D. Blockmans, A. Mathieu, H. Direskeneli, M. Galeazzi, A. Gül, Y. Levy, P. Petera, R. Popović, R. Petrovic, R. Sinico, R. Cattaneo, J. Font, G. Depresseux, J. Cosyns, R. Cervera (2002)
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.Arthritis and rheumatism, 46 8
-
Y. Meur, M. Büchler, A. Thierry, S. Caillard, F. Villemain, S. Lavaud, I. Étienne, P. Westeel, B. Ligny, L. Rostaing, E. Thervet, J. Szelag, J. Rerolle, A. Rousseau, G. Touchard, P. Marquet (2007)
Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal TransplantationAmerican Journal of Transplantation, 7
-
Z. Blumenfeld, D. Shapiro, M. Shteinberg, I. Avivi, M. Nahir (2000)
Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapyLupus, 9
-
T. Chan, F. Li, C. Tang, R. Wong, G. Fang, Y. Ji, C. Lau, A. Wong, M. Tong, K. Chan, K. Lai (2000)
Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.The New England journal of medicine, 343 16
-
T. Chan, K. Tse, C. Tang, M. Mok, Fu‐Keung Li (2005)
Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.Journal of the American Society of Nephrology : JASN, 16 4
-
C. Grootscholten, I. Bajema, S. Florquin, E. Steenbergen, C. Peutz-Kootstra, R. Goldschmeding, M. Bijl, E. Hagen, H. Houwelingen, R. Derksen, J. Berden (2007)
Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.Arthritis and rheumatism, 56 3
-
C. Grootscholten, G. Ligtenberg, E. Hagen, A. Bake, J. Glas-Vos, M. Bijl, K. Assmann, J. Bruijn, J. Weening, H. Houwelingen, R. Derksen, J. Berden (2006)
Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial.Kidney international, 70 4
-
M. Dooley, S. Hogan, C. Jennette, R. Falk (1997)
Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network.Kidney international, 51 4
-
F. Houssiau, David D'Cruz, H. Haga, Graham Hughes (1991)
Short Course of Weekly Low-Dose Intravenous Pulse Cyclophosphamide in the Treatment of Lupus Nephritis: A Preliminary StudyLupus, 1
-
H. Austin, J. Klippel, J. Balow, N. Riche, A. Steinberg, P. Plotz, J. Decker (1986)
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.The New England journal of medicine, 314 10
-
M. Gourley, Howard III, D. Scott, Cheryl Yarboro, E. Vaughan, J. Muir, D. Boumpas, J. Klippel, J. Balow, A. Steinberg (1996)
Methylprednisolone and Cyclophosphamide, Alone or in Combination, in Patients with Lupus NephritisAnnals of Internal Medicine, 125
-
M. Hachmi, M. Jadoul, C. Lefèbvre, G. Depresseux, F. Houssiau (2003)
Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcomeLupus, 12
-
F. Houssiau, C. Vasconcelos, D. D'cruz, G. Sebastiani, E. Garrido, M. Danieli, D. Abramovicz, D. Blockmans, A. Mathieu, H. Direskeneli, M. Galeazzi, A. Gül, Y. Levy, P. Petera, R. Popović, R. Petrovic, R. Sinico, R. Cattaneo, J. Font, G. Depresseux, J. Cosyns, R. Cervera (2004)
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.Arthritis and rheumatism, 50 12
-
R. Flanc, M. Roberts, G. Strippoli, S. Chadban, P. Kerr, R. Atkins (2004)
Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials.American journal of kidney diseases : the official journal of the National Kidney Foundation, 43 2
-
H. Haga, David D'Cruz, Ronald Asherson, Graham Hughes (1992)
Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis.Annals of the Rheumatic Diseases, 51
-
F. Houssiau (2004)
Management of lupus nephritis: an update.Journal of the American Society of Nephrology : JASN, 15 10
-
I. Bajema, Suzanne Wilhelmus, C. Alpers, Jan Bruijn, Robert Colvin, Terry Cook, Vivette D’Agati, Franco Ferrario, Mark Haas, J. Jennette, Kensuke Joh, Cynthia Nast, Laure-Hélène Noël, Emilie Rijnink, Ian Roberts, Surya Seshan, Sanjeev Sethi, A. Fogo, C. Jennette (2003)
Lupus nephritis -
(2006)
Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 weeks -
J. Killen (2006)
Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis.The New England journal of medicine, 354 7
-
T. Chan, F. Li, C. Tang, R. Wong, G. Fang, Y. Ji, C. Lau, A. Wong, M. Tong, Kwok Chan, K. Lai (2000)
Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus NephritisChinese Journal of Integrated Traditional and Western Nephrology
- Publisher
- SAGE
- Copyright
- Copyright © 2019 by SAGE Publications
- ISSN
- 0961-2033
- eISSN
- 1477-0962
- DOI
- 10.1177/0961203308090029
- Publisher site
- See Article on Publisher Site
Abstract
This review on the management of lupus nephritis is based on the results of randomized clinical trials, and discusses the principles of treatment and the current options for induction and maintenance therapy. The respective place of mycophenolate mofetil and intravenous cyclophosphamide are balanced, taking into account efficacy, safety and patients’ perspective. The authors anticipate that, in a few years, when long-term data on lupus nephritis patients induced with mycophenolate mofetil becomes available, it is probably that intravenous cyclophosphamide, which has been for so long the ‘standard of care’, will be prescribed only in specialized conditions such as documented necrotizing vasculitis.
Journal
Lupus – SAGE
Published: May 1, 2008